Clinical Trial Details
— Status: Withdrawn
Administrative data
NCT number |
NCT03196115 |
Other study ID # |
BHFS 06-2018 |
Secondary ID |
|
Status |
Withdrawn |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 20, 2018 |
Est. completion date |
February 28, 2021 |
Study information
Verified date |
February 2023 |
Source |
CENTOGENE GmbH Rostock |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Hyaline
fibromatosis syndrome from the blood
Description:
Hyaline fibromatosis syndrome (HFS) is rare autosomal recessive disease characterized by the
deposition of amorphous hyaline material in skin and visceral organs. It represents a disease
spectrum with infantile systemic hyalinosis (ISH) being the severe form and juvenile hyaline
fibromatosis (JHF) being the mild form. Dermatologic manifestations include thickened skin,
perianal nodules, and facial papules, gingival hyperplasia, large subcutaneous tumors on the
scalp, hyperpigmented plaques over the metacarpophalangeal joints and malleoli, and joint
contractures. ISH shows a severe visceral involvement, recurrent infections, and early death.
The lesions appear as pearly papules or fleshy nodules. The severity is variable. Some
individuals present in infancy and have additional visceral or systemic involvement, which
can lead to early death. These patients may show intractable diarrhea and increased
susceptibility to infection. Other patients have later onset of a milder disorder affecting
only the face and digits. Additional features include gingival hypertrophy, progressive joint
contractures resulting in severe limitation of mobility, osteopenia, and osteoporosis.
Histologic analysis of skin lesions shows proliferation of spindle-shaped cells forming
strands in a homogeneous and hyaline eosinophilic extracellular material in the dermis.
New methods, like mass-spectrometry give a good chance to characterize specific metabolic
alterations in the blood of affected patients that allow diagnosing in the future the disease
earlier, with a higher sensitivity and specificity.
Therefore it is the goal of the study to identify and validate a new biochemical marker from
the blood of the affected patients helping to benefit other patients by an early diagnose and
thereby with an earlier treatment.